Therapy News and Research

RSS

Study shows association between chemotherapy benefit and menopausal status in breast cancer patients

After a median follow-up of 5.1 years, among women with lymph node-positive early-stage breast cancer and a recurrence score of 25 or lower who received adjuvant endocrine therapy with or without chemotherapy, postmenopausal patients had no added benefit from chemotherapy, while premenopausal patients who received chemotherapy had improved invasive disease-free survival (IDFS) and an early indication of improved overall survival (OS), according to data from the SWOG S1007 RxPONDER clinical trial presented at the 2020 San Antonio Breast Cancer Symposium, held Dec. 8-11.

9 Dec 2020

Tomatoes could become a new, natural source of Parkinson's disease drug

Scientists have produced a tomato enriched in the Parkinson's disease drug L-DOPA in what could become a new, affordable source of one of the world's essential medicines.

9 Dec 2020

Study reveals new biomarker for amyotrophic lateral sclerosis

ALS is a fatal neurodegenerative disease causing a rapid loss of motor function, which usually results in a serious condition with early death within a few years.

9 Dec 2020

Repair protein may prevent damage to healthy cells during cancer therapy

A key way radiation therapy and chemotherapy work is by making highly lethal double-strand breaks in the DNA of cancer cells.

9 Dec 2020

People with Bartonella infection exhibit neuropsychiatric symptoms, skin lesions

Bartonella bacteria are increasingly recognized as an emerging infectious disease threat. A new study by North Carolina State University researchers has found additional instances of Bartonella infection in humans who exhibited neuropsychiatric symptoms, a subset of whom also had skin lesions.

8 Dec 2020

GlycoNet scientists secure up to $4 million US investment to advance regenerative medicine

GlycoNet scientists Drs. Robert Ben and Jason Acker, who are revolutionizing the cryopreservation of cells, tissues and organs for human and veterinary therapies, have secured a $2-million USD equity investment for PanTHERA CryoSolutions (PanTHERA), a Canadian biotechnology start-up that they co-founded.

8 Dec 2020

Possible new antibiotic developed for drug-resistant pulmonary pathogen

Scientists from Johns Hopkins University and Medicine have developed a possible new antibiotic for a pathogen that is notoriously resistant to medications and frequently lethal for people with cystic fibrosis and other lung ailments.

8 Dec 2020

Research shows how targeted microbubbles can carry powerful cancer drugs

New research has shown how microbubbles carrying powerful cancer drugs can be guided to the site of a tumor using antibodies.

8 Dec 2020

OU Health Sciences Center receives federal grant for opioid management in older adults

Chronic pain can be quite common among older adults as they face conditions such as arthritis and neuropathy. Treating pain in older adults requires special considerations, however, especially when it comes to opioids.

8 Dec 2020

Novel antibody-drug conjugate shows 29% response rate in rare blood cancer

Early study data shows a 29% overall response rate, the favorable safety profile in blastic plasmacytoid dendritic cell neoplasm (BPDCN)

8 Dec 2020

Study examines effect of low-dose vancomycin to treat clostridium difficile infection

Clostridium difficile infection (CDI) is inflammation of the colon caused by a bacteria called clostridium difficile and is the most common cause of infectious diarrhea in hospitalized patients.

8 Dec 2020

Researchers use novel technology to prevent destruction of specific proteins inside cells

Columbia researchers have created a new technology using synthetic llama antibodies to prevent specific proteins from being destroyed inside cells.

8 Dec 2020

Phase I/IIA open-label study presents encouraging results on hard-to-treat AML subtypes

Novel menin-KMT2A inhibitor appears to be safe and well-tolerated. FLT3 inhibitor plus low-dose chemotherapy shows promising efficacy and safety. Results represent encouraging news on hard-to-treat AML subtypes.

7 Dec 2020

Study highlights previously unknown mechanisms involved in myeloma resistance

A group of researchers led by Maximillian Merz, MD, Assistant Professor of Oncology with the Myeloma team at Roswell Park Comprehensive Cancer Center, conducted the first prospective clinical trial investigating spatial heterogeneity in patients with either relapsed/refractory or newly diagnosed multiple myeloma.

7 Dec 2020

Researchers evaluate safety of novel therapy for patients with non-Hodgkin lymphoma

Roswell Park Comprehensive Cancer Center's Francisco J. Hernandez-Ilizaliturri, MD, along with a team of researchers from other institutions, has been investigating a novel therapy for patients with relapsed or refractory B-cell non-Hodgkin lymphoma.

7 Dec 2020

Study: Caplacizumab not cost effective for treating thrombotic thrombocytopenic purpura

In a new study by Yale Cancer Center researchers, the drug caplacizumab is shown not to be cost-effective in treating thrombotic thrombocytopenic purpura (TTP) when added to the standard-of-care.

7 Dec 2020

Drug prescribed for rare enzyme deficiency shows promise to treat herpes viruses

A drug currently prescribed to treat a rare enzyme deficiency can help cells clear the herpes simplex 1 and herpes simplex 2 viruses, according to a new study published in the journal Science Advances.

7 Dec 2020

Chemotherapy combined with blinatumomab increases survival for patients with Ph-negative B-ALL

A study led by The University of Texas MD Anderson Cancer Center showed that first-line treatment with a regimen of chemotherapy combined with the monoclonal antibody blinatumomab resulted in increased survival and achieved a high rate of measurable residual disease (MRD) negativity for patients who were newly diagnosed with a high-risk form of acute lymphoblastic leukemia (ALL) known as Philadelphia chromosome-negative B-cell ALL (Ph-negative B-ALL).

7 Dec 2020

Study finds CAR T cell therapy as effective as first-line treatment for high-risk large B-cell lymphoma

A study led by researchers at The University of Texas MD Anderson Cancer Center found that axi-cel, an autologous anti-CD19 chimeric antigen receptor (CAR) T cell therapy, is a safe and effective first-line therapy for patients with high-risk large B-cell lymphoma (LBCL), a group with an urgent need for new and effective treatments.

7 Dec 2020

Researchers develop potential non-drug, non-surgical, long-acting therapy for glaucoma

Researchers have developed a potential new treatment for the eye disease glaucoma that could replace daily eye drops and surgery with a twice-a-year injection to control the buildup of pressure in the eye.

7 Dec 2020

Therapy News and Research

Study shows association between chemotherapy benefit and menopausal status in breast cancer patients

Tomatoes could become a new, natural source of Parkinson's disease drug

Study reveals new biomarker for amyotrophic lateral sclerosis

Repair protein may prevent damage to healthy cells during cancer therapy

People with Bartonella infection exhibit neuropsychiatric symptoms, skin lesions

GlycoNet scientists secure up to $4 million US investment to advance regenerative medicine

Possible new antibiotic developed for drug-resistant pulmonary pathogen

Research shows how targeted microbubbles can carry powerful cancer drugs

OU Health Sciences Center receives federal grant for opioid management in older adults

Novel antibody-drug conjugate shows 29% response rate in rare blood cancer

Study examines effect of low-dose vancomycin to treat clostridium difficile infection

Researchers use novel technology to prevent destruction of specific proteins inside cells

Phase I/IIA open-label study presents encouraging results on hard-to-treat AML subtypes

Study highlights previously unknown mechanisms involved in myeloma resistance

Researchers evaluate safety of novel therapy for patients with non-Hodgkin lymphoma

Study: Caplacizumab not cost effective for treating thrombotic thrombocytopenic purpura

Drug prescribed for rare enzyme deficiency shows promise to treat herpes viruses

Chemotherapy combined with blinatumomab increases survival for patients with Ph-negative B-ALL

Study finds CAR T cell therapy as effective as first-line treatment for high-risk large B-cell lymphoma

Researchers develop potential non-drug, non-surgical, long-acting therapy for glaucoma

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News